Controlled Substances Market Projected to Witness a Single-Digit CAGR During 2018 to 2028 | Key Players are Mallinckrodt plc, The Peace Naturals Project, Canopy Growth Corporation, etc.

In order to dissert the market scenario prevailing across the controlled substances market sector, Fact.MR has evenly presented a comprehensive analysis report on controlled substances market to its extensive online repository. With all vital market facets enclosed into this single assessment, readers can learn about different market drivers, opportunities and trends which are likely to influence the overall market space for the controlled substances market in the coming years. In addition, factors such as market size, Y-o-Y growth and revenue share are investigated so as to make this research highly authentic and reliable.

Request for a Free Sample Report of Concerned Market - https://www.factmr.com/connectus/sample?flag=S&rep_id=2032

Controlled Substances Market – Key Insights 

The controlled substances market registered a CAGR of over 3% during the period, 2013 to 2017. Sales of controlled substances are expected to remain underpinned by efforts of mature markets in reducing costs to create an affordable landscape for end-users.
The controlled substances market was valued in excess of US$ 42,000 Mn in 2018, and is projected to record a modest expansion at 4% CAGR through 2028.
North America has traditionally been the most lucrative market for controlled substances, with sales estimated to record a Y-o-Y of 3.5% in 2019 over 2018. This can be attributes in part to legalization of various forms of marijuana in the US, along with the recent approval of recreational marijuana sales in Canada.
Latin America is expected to exhibit the fastest growth in the controlled substances market through 2028. Uruguay, and Colombia continue to gain significance as an attractive market for medical marijuana in Latin America, in light of their emerging stature. 
What are Key Growth Influencers of the Controlled Substances Market? 

Adoption of controlled substances for management & treatment of a wide range of medical conditions, including obesity, diarrhea suppression, and refractory exogenous obesity. This has resulted in an expanding patient pool in the marketplace, in turn creating lucrative growth opportunities.
There has been a notable rise in advertisement campaigns apropos of public awareness on use of controlled substances, with regard to their licensing, registration, use, and storage, which in turn is upholding sales.
Growing preference for medical marijuana over prescription drugs for managing headaches, depression, back problems, and pain, despite criminalization, alludes current public health framework that deems cannabis abstinence becoming obsolete.
The WHO has been taking immense efforts for improving the access to controlled substances, by collaborating with producers and suppliers across countries with potential growth. These efforts are directed toward capacity building of dispensers & prescribers, along with the development of balanced legislation and policies.
Controlled Substances Market – Competition Landscape 

GW Pharmaceuticals has announced its plan of epidiolex (CBD or cannabidiol) development program in 2018, to combat infantile spasms, which according to the company is the fourth largest target indication for its program of epidiolex orphan pediatric epilepsy development.
Molecular Science Corporation and Canopy Growth entered into a strategic collaboration in 2018, to pioneer standardized testing methods for analyzing and enhancing the efficacy of cannabis testing, its safety awareness and product knowledge.
Aphria Incorporation has signed an exclusive agreement with Colcanna SAS for extending its medical cannabis sales in Columbia. Aphria eyes to leverage the large distribution footprint of Colcanna SAS to market its MMJ products in Columbia.
Key players operating in the controlled substances market, as identified in the report, include CANNABIS SATIVA, INC., The Peace Naturals Project, Canopy Growth Corporation, GW PHARMACEUTICALS PLC, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals, Inc., Mallinckrodt plc, SAFC/Cerilliant, Noramco, Inc., Johnson Matthey, Siegfried AG, AMRI, Cayman Chemical, Consort Medical, Patheon, and Cambrex. 

Research Methodology 

This report offers holistic insights on the controlled substances market, along with important numbers such as revenue comparison, Y-o-Y growth comparison, and market share comparison of key segmented identified in the controlled substances market. Key trend affecting the growth of the controlled substances market have also been analyzed in the report, along with their degree of impact intensity on the controlled substances market. Insights and analysis offered on the controlled substances market in this report are backed by a robust research methodology, which involves a perfect combination of extensive primary and secondary researches. The year 2017 is considered as the base year for forecasting further projections of the controlled substances market for the period between 2018 and 2028. Comprehensive telephonic interviews have been conducted for gaining first-hand, authoritative information on the controlled substances market’s current scenario and prospects. This information is then used for validating the insights gained from exhaustive secondary researches. 

Ask Industry Experts about this Report - https://www.factmr.com/connectus/sample?flag=AE&rep_id=2032

Contact Us
FactMR
11140 Rockville Pike
Suite 400, Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at: https://insiderstribune.com

About FactMR

FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

This release was published on openPR.